Molecular Pharmacology Program
The Michael Kharas Lab
Research
The Kharas lab is working to identify critical pathways in both normal and leukemic hematopoietic cells.
Featured News
Publications Highlights
Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation. Agarwal G, Antoszewski M, Xie X, Pershad Y, Arora UP, Poon CL, Lyu P, Lee AJ, Guo CJ, Ye T, Norford LB, Neehus AL, Della Volpe L, Wahlster L, Ranasinghe D, Ho TC, Barlowe TS, Chow A, Schurer A, Taggart J, Durham BH, Abdel-Wahab O, McGraw KL, Allan JM, Soldatov R, Bick AG, Kharas MG, Sankaran VG. Science. 2026 Jan;391(6780):52-58. doi: 10.1126/science.adx4174. Epub 2026 Jan 1. PMID: 41477881; PMCID: PMC12850507.
SON is an essential m6A target for hematopoietic stem cell fate. Luo H, Cortés-López M, Tam CL, Xiao M, Wakiro I, Chu KL, Pierson A, Chan M, Chang K, Yang X, Fecko D, Han G, Ahn EE, Morris QD, Landau DA, Kharas MG. Cell Stem Cell. 2023 Dec 7;30(12):1658-1673.e10. doi: 10.1016/j.stem.2023.11.006. PMID: 38065069; PMCID: PMC10752439.
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cheng Y, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, Luo H, Nguyen DT, Mo S, Barin E, Velleca A, Rohwetter TM, Patel DJ, Jaffrey SR, Kharas MG. Cancer Cell. 2021 Jul 12;39(7):958-972.e8. doi: 10.1016/j.ccell.2021.04.017. Epub 2021 May 27. PMID: 34048709; PMCID: PMC8282764.
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, Melnick A, Carroll M, Mason CE, Jaffrey SR, Kharas MG. Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18. PMID: 28920958; PMCID: PMC5677536.
High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells. Jeong S, Savino AM, Chirayil R, Barin E, Cheng Y, Park SM, Schurer A, Mullarky E, Cantley LC, Kharas MG, Keshari KR. Cell Metab. 2021 Jan 5;33(1):145-159.e6. doi: 10.1016/j.cmet.2020.12.005. Epub 2020 Dec 22. PMID: 33357456; PMCID: PMC8168776.
People
Michael G. Kharas, PhD
- Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.
- PhD, University of California Irvine
- [email protected]
- Email Address
Members
- BS, College of St. Scholastica
- Cancer Biology
- BS, Portland State University
- Dai hoc Quoc Gia Hanoi
Achievements
- Leukemia and Lymphoma Society Career Development Award (2017)
- Alex Lemonade Stand Foundation ‘A’ Award (2016)
- American Society of Hematology Junior Faculty Scholar Award (2011)
- Kimmel Scholar Award (2013)
- V-Scholar Award (2013)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Research Technician
As a Research Technician you will perform research activities in collaboration with internal/external personnel to complete science-based projects. You will normally receive detailed instructions while making observations, analyzing data and interpreting results according to laboratory procedures. The Research Technician will provide support to all technical/research staff and postdocs.
Get in Touch
-
Lab Head Email
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Michael G. Kharas discloses the following relationships and financial interests:
-
858 Therapeutics, Inc.
Equity; Professional Services and Activities -
AstraZeneca
Professional Services and Activities
-
Transition Bio, Inc.
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].